Close Menu
NEW YORK – ERS Genomics said on Tuesday that it has signed a licensing agreement granting Aelian Biotechnology access to its CRISPR-Cas9 patent portfolio to support Aelian's commercial functional genomic screening platform.
 
Aelian, based in Vienna, combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.